XBI News 134.09 04/22/2014 18:44:41 SPDR S&P Biotech (XBI)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
SPDR S&P Biotech (XBI) 134.09 $XBI

Shares of XBI Down 21.2% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Mon Apr 21, 11:17AM CDT
SmarTrend identified a Downtrend for SPDR S&P Biotech ETF (AMEX:XBI) on March 7th, 2014 at $160.16. In approximately 2 month, SPDR S&P Biotech ETF has returned 21.15% as of today's recent price of $126.28.

1 of These 3 Cratering Biotechs is a Buy
George Budwell, The Motley Fool - Motley Fool - Fri Apr 18, 5:30PM CDT
At the start of the year, the theme seemed to be that biotech was in for another banner year, propelled by a suite of newly launch drugs that would go on to become blockbusters. These rosy prognostications were made despite broad-based biotech funds...

After Yesterday's Decline of 1.71%, SPDR S&P Biotech ETF Offers Investors Better Value
Comtex SmarTrend(R) - Mon Apr 14, 4:02PM CDT
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $119.06 to a high of $127.86. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $123.85 on volume of 1.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Biotech Is Officially in a Bear Market. Is It Time to Panic?
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 12, 3:03PM CDT
There was once a time when the biotech sector could do no wrong. Venture capital was literally coming up out of the floor to invest in the latest new development platforms. Secondary offerings were also being met with plenty of buyers. And let's not...

SPDR S&P Biotech ETF Shares Down 18.7% Since SmarTrend's Sell Call (XBI)
Comtex SmarTrend(R) - Fri Apr 11, 11:11AM CDT
SmarTrend identified a Downtrend for SPDR S&P Biotech ETF (AMEX:XBI) on March 7th, 2014 at $160.16. In approximately 1 month, SPDR S&P Biotech ETF has returned 18.71% as of today's recent price of $130.19.

Jim Cramer's Mad Dash: HRB GILD
at The Street - Fri Apr 11, 9:38AM CDT
The tax man cometh and shows no sign of leaving, which means good news for H&R Block as it spins off its banking division, Cramer says.

Inside the Wild Ride of Biotech ETFs - ETF News And Commentary
Eric Dutram - Zacks Investment Research - Fri Apr 11, 9:01AM CDT
Biotech ETFs have been crashing, but have all the funds been performing the same in the space?

After Yesterday's Decline of 6.40%, SPDR S&P Biotech ETF Offers Investors Better Value
Comtex SmarTrend(R) - Thu Apr 10, 5:14PM CDT
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $128.38 to a high of $139.22. Yesterday, the shares fell 6.4%, which took the trading range below the 3-day low of $129.76 on volume of 1.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

'Fast Money' Recap: The Profit-Taking Spreads
at The Street - Tue Apr 08, 4:00AM CDT
The trading panel discussed how investors are selling all sorts of sectors, including steel and home improvement.

SPDR S&P Biotech ETF Down 12.4% Since SmarTrend Downtrend Call (XBI)
Comtex SmarTrend(R) - Fri Apr 04, 9:59AM CDT
SmarTrend identified a Downtrend for SPDR S&P Biotech ETF (AMEX:XBI) on March 7th, 2014 at $160.16. In approximately 4 weeks, SPDR S&P Biotech ETF has returned 12.45% as of today's recent price of $140.22.

SmarTrend Watching for Potential Rebound in Shares of SPDR S&P Biotech ETF After 3.56% Loss
Comtex SmarTrend(R) - Thu Apr 03, 4:37PM CDT
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $137.59 to a high of $144.94. Yesterday, the shares fell 3.6%, which took the trading range below the 3-day low of $138.06 on volume of 932,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Any Survivors from the Biotech ETF Meltdown? - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Mon Mar 31, 3:00PM CDT
Although all biotech ETFs crumbled last week, many might still be well positioned for the future.

3 ETFs to Watch as Obamacare Hits Deadline - ETF News And Commentary
Sweta Killa - ZACKS - Mon Mar 31, 1:00PM CDT
Expectation for a larger base of insurers under the Obamacare put these healthcare ETFs in focus for the coming weeks.

10.3% Return Seen to Date on SmarTrend SPDR S&P Biotech ETF Call (XBI)
Comtex SmarTrend(R) - Thu Mar 27, 10:05AM CDT
SmarTrend identified a Downtrend for SPDR S&P Biotech ETF (AMEX:XBI) on March 7th, 2014 at $160.16. In approximately 3 weeks, SPDR S&P Biotech ETF has returned 10.29% as of today's recent price of $143.67.

SPDR S&P Biotech ETF Set to Possibly Rebound After Yesterday's Selloff of 3.25%
Comtex SmarTrend(R) - Wed Mar 26, 5:02PM CDT
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $141.41 to a high of $148.38. Yesterday, the shares fell 3.3%, which took the trading range below the 3-day low of $142.63 on volume of 1.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Cracks Beneath the Market's Surface
at The Street - Tue Mar 25, 10:45AM CDT
Even though the market has hit new highs, weakness lurks below. What should you do as an investor?

'Fast Money' Recap: The Value of 'Old Tech' Stocks
at The Street - Tue Mar 25, 4:00AM CDT
The trading panel discussed why these stocks have solid upside momentum and reasonable valuations.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

GomSpace's €8M Lunar Deal Pushes Mission Ambitions

Updated Category News Views 63

Moon hardware is where small-space dreams either grow teeth or chew through cash, and GomSpace has just taken another meaningful bite. The company has secured an €8 million, or 89.1 million Swedish kronor, contract for the second phase of a lunar mission program with an unnamed leading North American space company. For GOMX, this is not some vague laboratory...

Continue Reading
Northstar's December Test: Metrics Over More Promises

Updated Category News Views 43

A shingle recycler earns its stripes when the machinery behaves, not when the slide deck does. Northstar Clean Technologies is putting Empower Calgary under a brighter light on December 1, pairing its third-quarter 2026 results with a comprehensive production update and a new set of operating metrics. For shareholders, especially those following OTCQB:ROOOF, this is the...

Continue Reading
Robert Half's Parent Support Earns Fortune Recognition

Updated Category News Views 73

A workplace award rarely moves a staffing stock by itself, and it shouldn’t. Still, Fortune naming Robert Half among its Best Workplaces for Parents for 2026 is more than decorative corporate wallpaper. In the talent business, the company’s own ability to recruit, retain and support people is part of the product. Clients hire Robert Half because they need skilled...

Continue Reading
Holland America Puts 2028 Alaska Demand on Display

Updated Category News Views 123

Alaska’s interior is where a cruise brochure either earns its keep or gets exposed. Holland America Line is opening bookings for 2028 Alaska Cruisetours nearly two years ahead, tying a coast-and-land product to the reimagined Oosterdam’s Alaska debut. That is not merely another itinerary release. It is a fairly deliberate attempt to sell a bigger, longer and...

Continue Reading
FAA Funding Gridlock Raises Aviation Reliability Risk

Updated Category News Views 81

Friday’s radar and communications trouble delivered the sort of warning nobody in aviation can shrug off: the machinery behind the flight board is getting old, fragile, and far too dependent on people improvising around it. Thousands of flights were delayed or canceled when air traffic control facilities became unstable, according to the Southwest Airlines Pilots...

Continue Reading
LKQ’s Europe ERP Mess Turns Into a Credibility Test

Updated Category News Views 60

A software rollout should not be able to punch a company in the teeth twice, yet LKQ shareholders have watched precisely that ugly movie in 2026. The October 23 disclosure was a real gut-check: an immediate CEO departure, a $16 million net loss, and renewed acknowledgement that the German enterprise-resource-planning rollout was disrupting Europe. Shares fell $5.05, or...

Continue Reading
L’Oréal’s Women of Worth Shows Why Brand Patience Matters

Updated Category News Views 105

Twenty-one years is a long time to keep a corporate promise from turning into wallpaper. L’Oréal Paris gathered its 2026 Women of Worth class at the Ebell in Los Angeles on November 18, recognizing 10 nonprofit leaders working on problems that do not yield to a glitzy evening or a tidy slogan. That distinction matters. Cancer survivorship, trafficking prevention,...

Continue Reading
Yiwu Squishies Turn Viral Demand Into Factory Backlogs Worldwide

Updated Category News Views 87

A pizza-shaped stress toy booking more than one million units is the sort of detail that makes a jaded market watcher sit up before rolling his eyes at the word “viral.” Yiwu’s squishy-toy surge appears to have moved beyond a few social-media impulses and into actual factory scheduling, repeat purchase orders and supermarket procurement. That is meaningful. It is...

Continue Reading
Colossal's Halloween Campaign Wins Top Communicator Honor

Updated Category News Views 76

A horror-themed fan competition putting money toward hospitalized children is not the usual awards-season material, which is precisely why Colossal's latest recognition lands with some weight. The Phoenix-based professional fundraiser received an Award of Excellence, the top honor at the 32nd annual Communicator Awards, for its Face of Halloween campaign in the Innovation...

Continue Reading
Innogen's Arcera Deal Tests Its GLP-1 Global Reach

Updated Category News Views 115

A License Deal With Actual Cash Attached Drug licensing announcements can smell like expensive perfume: plenty of promise, hard to tell what is really in the bottle. This one at least arrives with a concrete number. Innogen Pharmaceuticals will receive US$38 million in upfront and near-term milestone payments from Arcera Life Sciences for Efsubaglutide Alfa, including a...

Continue Reading

Top 5 Most Recently Viewed Articles

How a $100 Investment in Builders FirstSource Transformed

Updated Category News Views 173

Understanding Builders FirstSource's Growth Journey Investing in the stock market can sometimes feel daunting, but Builders FirstSource (NYSE: BLDR) has presented an impressive case for savvy investors over the last five years. This company has not only survived the ups and downs of the market but has also outperformed it significantly. With a remarkable 28.17% annualized...

Continue Reading
Adagene Strengthens Leadership with Axel Hoos as Advisor

Updated Category News Views 99

Adagene Appoints Renowned Immuno-Oncology Expert Adagene Inc. (Nasdaq: ADAG) has marked a significant milestone in its journey towards transforming cancer treatment by appointing Dr. Axel Hoos as an Executive Advisor. With an impressive background in immuno-oncology, Dr. Hoos brings a wealth of knowledge and experience that aligns perfectly with Adagene's mission....

Continue Reading
Suffolk County Transit Orders 132 Modern Buses from NFI

Updated Category News Views 122

NFI Group Inc. Awarded Contract for New Buses A recent agreement between NFI Group Inc. and Suffolk County Transit has been finalized, marking an essential step in modernizing the county's public transportation system. The contract, which spans five years, encompasses the delivery of up to 132 next-generation buses, including a combination of hybrid-electric and...

Continue Reading
Decoding Love: The Real Patterns of Relationships

Updated Category News Views 131

The Relationship Maze: More Than Meets the Eye Love ain't just a simple spark over a fancy dinner, let me tell you. In Dr. Bernadette Marson’s ‘The Relationship Code,’ she digs into seventy-seven elements gnawing at why relationships can crumble or thrive. It’s like a blueprint of human entanglements—a veritable explorer’s guide to the vast, wild creation we...

Continue Reading
Understanding BP's Recent Options Activity and Market Insights

Updated Category News Views 129

Understanding BP's Options Activity Investors with substantial capital have recently adopted a positive outlook on BP. This inspires interest among retail traders. Our analysis of publicly available options data indicates notable trading activity involving BP. An uptick of this nature often hints that informed investors anticipate significant developments regarding the...

Continue Reading